UK health agency concerned with antibiotic resistance
LONDON The United Kingdom’s Health Protection Agency has said that efforts to address antibiotic-resistant staphylococcus had been successful, but health officials also face threats from other bacteria.
The agency has warned the National Health Service against overuse of antibiotics while suggesting the pharmaceutical industry do research to develop new drugs as 12 percent of E. coli infections in the U.K. were becoming resistant to antibiotics.
The HPA said that development of antibiotics to treat the bacteria family to which E. coli belongs, called Gram-negative bacteria, had lagged compared to antibiotics against Gram-positive bacteria, such as methicillin-resistant staphylococcus aureas.
Glue-like bacterial sugar could lead to vaccine
LONDON A study has found that when manipulated with chemicals, a sugar that drug-resistant bacteria secrete triggered an immune response in animals.
The study, presented last week at the Dublin, Ireland, meeting of the Society for General Microbiology used a glue-like sugar that bacteria produce to protect themselves from antibiotics called PNAG.
PNAG alone does not produce an immune response in most people and animals, but the researchers, from the Harvard Medical School, hope that formulations of it do.
FDA announces likely delay on Novo Nordisk diabetes drug
WASHINGTON The Food and Drug Administration has announced that it will be unable to meet the user fee deadline for a timely approval of Novo Nordisk’s drug liragludite.
The FDA will not be able to make an approvability decision until March 23 for the drug, a treatment for Type 2 diabetes. Novo Nordisk had submitted an approval application for the drug on May 23.
The standard review period for FDA action on approval applications is 10 months. Because the agency’s advisory committee meeting will take place shortly before March 23, however, its decision will probably be delayed by a further two months, the company said.